Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “outperform” rating reaffirmed by equities researchers at Leerink Swann in a report released on Friday. They presently have a $15.00 price target on the biotechnology company’s stock. Leerink Swann’s target price indicates a potential upside of 67.97% from the company’s previous close.

A number of other research firms have also commented on ADAP. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Zacks Investment Research lowered shares of Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $12.08.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded up 18.28% during mid-day trading on Friday, hitting $8.93. 1,710,060 shares of the stock traded hands. The firm’s market capitalization is $835.12 million. The company’s 50 day moving average is $5.62 and its 200 day moving average is $5.16. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $8.95.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, hitting analysts’ consensus estimates of ($0.24). Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. The business had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. On average, equities analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/adaptimmune-therapeutics-plcs-adap-outperform-rating-reaffirmed-at-leerink-swann.html.

Institutional investors have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. acquired a new stake in Adaptimmune Therapeutics PLC during the first quarter worth about $120,000. KCG Holdings Inc. acquired a new stake in Adaptimmune Therapeutics PLC during the first quarter worth about $133,000. Monashee Investment Management LLC acquired a new stake in Adaptimmune Therapeutics PLC during the first quarter worth about $138,000. Paloma Partners Management Co acquired a new stake in Adaptimmune Therapeutics PLC during the first quarter worth about $165,000. Finally, OxFORD Asset Management LLP acquired a new stake in Adaptimmune Therapeutics PLC during the second quarter worth about $156,000. Hedge funds and other institutional investors own 68.01% of the company’s stock.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.